Jeffrey Wolf

Jeffrey Wolf, MD, is a Professor in the Department of Medicine at the University of California, San Francisco (UCSF), School of Medicine. He serves as the Director of the Myeloma Program, where he leads clinical and translational research focused on multiple myeloma and plasma cell disorders. His work emphasizes novel immunotherapies, including CAR-T cells, bispecific antibodies, and targeted agents, with a strong commitment to improving patient outcomes through clinical trials.

Dr. Wolf’s research interests center on advancing therapeutic strategies for multiple myeloma, particularly BCMA, GPRC5D, CD38, and CD70-targeted therapies. His laboratory and clinical studies explore mechanisms of treatment resistance, T-cell exhaustion, immune-related toxicities, and the myeloma surfaceome to identify new targets. He actively investigates the interplay between immunotherapy and host immunity, including vaccine responses in immunocompromised patients. His work spans from basic molecular mechanisms to phase 1 and 2 clinical trials, reflecting a robust translational approach.

The 15 most recent publications highlight a consistent focus on immunotherapeutic advances in multiple myeloma. Key themes include CAR-T cell therapy (BCMA, CD70), mechanisms of resistance and toxicity (e.g., T-cell exhaustion, enterocolitis, MAS-L), and novel antibody-based approaches (e.g., targeting GPRC5D, CD38). There is a strong emphasis on clinical translation, with multiple phase 1b and observational studies informing treatment optimization and patient management strategies.

• Director, Myeloma Program, UCSF
• Professor, Department of Medicine, UCSF School of Medicine
• Active principal or co-investigator on numerous clinical trials in multiple myeloma
• Extensive collaborations with leaders in hematology-oncology including Thomas Martin, Nina Shah, and Arun Wiita

Dr. Wolf has mentored numerous researchers and clinicians through his role at UCSF and has contributed to the training of hematologists and oncologists. While specific advisees are not listed in the provided text, his extensive co-authorship network suggests a strong commitment to collaborative science and academic mentorship. He has not received any explicitly listed scientific awards in the provided data, but his publication record in top-tier journals and leadership in clinical trials indicate significant recognition in the field.

His work is conducted within the UCSF Myeloma Program, a multidisciplinary team dedicated to research and treatment of plasma cell disorders. The program engages in cutting-edge translational research, clinical trial development, and patient care, with a focus on immunotherapy and personalized medicine approaches.